Document is current

Article History

Received: 10 April 2025

Accepted: 3 June 2025

First Online: 19 June 2025

Declarations

:

: Dra. Isla reports consulting honoraria from AbbVie, Amgen, AstraZeneca, Bayer, BMS, Beigene, Boehringer Ingelheim, F. Hoffmann-La Roche, Johnson & Johnson, Lilly, Merck, MSD, Pfizer, Pharmamar, Sanofi, Takeda and speaker honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, F. Hoffmann-La Roche, Johnson & Johnson, Lilly, MSD, Pfizer, Pharmamar, and Takeda. Also institutional financial interests in clinical trials from AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, F. Hoffmann-La Roche, GSK, Johnson & Johnson, Lilly, Merck, Mirati, MSD, Novartis, Pfizer, Pharmamar, Sanofi and research grants from AstraZeneca, BMS, F. Hoffmann-La Roche, and GSK. Dra. Conde reports serving in a consulting or advisory role for Johnson & Johnson, AstraZeneca, and Roche; receiving honoraria from Johnson & Johnson, AstraZeneca, Thermo Fisher, Roche, Lilly, and Pfizer; receiving research funding from Roche and Thermo Fisher. Dra. Romero has received the GECP grant sponsored by Janssen outside of the submitted work. Dra Garrido Siles reports serving in a consulting or advisory role for AstraZeneca, Takeda, and Roche: receiving support for attending meetings and/or travel from Roche, Merck Sharp & Dohme, and Novartis. Dr. Marin reports serving in a consulting or advisory role for Johnson & Johnson; receiving honoraria from Takeda, Daiichi Sankyo, Roche, AstraZeneca, and receiving support for attending meetings and/or Travel from Takeda, Merck Sharp & Dohme, Roche, Daiichi Sankyo and Boehringer Ingelheim. Dr. Massutí reports serving in a consulting or advisory role for Roche, BMS, Boehringer Ingelheim, Takeda, Beigene, Pharmamar and receiving support for attending meetings and/or travel from Roche, Pfizer, MSD, Astra-Zeneca. Dr. Abdulkader received honoraria for speaker, consultancy, or advisory role from Astra-Zeneca, Janssen, Merck-Serono, Roche, Pfizer, BMS, Lilly, Amgen, Astellas, MSD, and grant or travel support from Janssen, and Pfizer. Dra. Carreras reports serving in a consulting or advisory role, receiving honoraria from Johnson & Johnson; Novartis, Menarini Stemline España SLU, Jazz Pharmaceuticals, Takeda Pharmaceuticals international and Regeneron; and receiving support for attending meetings and/or Travel from Roche. Dra. Marina and Dr. Calderón are current employees of Johnson & Johnson. Dr. Gil-Bazo reports serving in a consulting or advisory role for Johnson & Johnson, Lilly, and Boehringer Ingelheim; receiving payment or honoraria from Johnson & Johnson, Amgen, AstraZeneca, Merck Sharp & Dohme, and Takeda; receiving support for attending meetings and/or travel from Johnson & Johnson, Merck Sharp & Dohme, Daiichi Sankyo, and Sanofi. The other authors declare that they have no conflict of interest.

: This study did not involve patients or access to patient data and was conducted solely with healthcare professionals. Accordingly, it was exempt from formal ethics committee review in accordance with national regulations.

: All participants received detailed information about the study's objectives and procedures. Informed consent was obtained by their voluntary completion of the first-round questionnaire.